Premium
Pharmacogenomic testing in depression has limited evidence base so far
Publication year - 2017
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30219
Subject(s) - pharmacogenomics , depression (economics) , psychiatry , citation , medicine , psychology , computer science , library science , pharmacology , economics , macroeconomics
Pharmacogenomic testing to inform the selection of an antidepressant has demonstrated limited evidence of effectiveness thus far, concludes a systematic review published online Jan. 3 in the Journal of Clinical Psychiatry . The relevant studies that have been conducted to this point have been weakened by methodological limitations and significant bias, researchers stated.